Cargando…

Improving CAR T-Cell Persistence

Over the last decade remarkable progress has been made in enhancing the efficacy of CAR T therapies. However, the clinical benefits are still limited, especially in solid tumors. Even in hematological settings, patients that respond to CAR T therapies remain at risk of relapsing due to several facto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pietrobon, Violena, Todd, Lauren Anne, Goswami, Anghsumala, Stefanson, Ofir, Yang, Zhifen, Marincola, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509430/ https://www.ncbi.nlm.nih.gov/pubmed/34639168 http://dx.doi.org/10.3390/ijms221910828

Ejemplares similares

Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment
por: Yang, Zhifen, et al.
Publicado: (2023)

Contextual reprogramming of CAR-T cells for treatment of HER2(+) cancers
por: Yang, Zhifen, et al.
Publicado: (2021)

Hypoxia and the phenomenon of immune exclusion
por: Pietrobon, Violena, et al.
Publicado: (2021)

Multifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
por: Lappano, Rosamaria, et al.
Publicado: (2022)

Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
por: Pietrobon, Violena, et al.
Publicado: (2021)

Current strategies employed in the manipulation of gene expression for clinical purposes
por: Tsai, Hsing-Chuan, et al.
Publicado: (2022)

Cancer metabolism
por: Pietrobon, Violena
Publicado: (2021)

Strategies to enhance CAR-T persistence
por: Liu, Yue, et al.
Publicado: (2022)

RNA-cDNA hybrids mediate transposition via different mechanisms
por: Todd, Lauren A., et al.
Publicado: (2020)

Lentiviral delivery of combinatorial CAR/CRISPRi circuit into human primary T cells is enhanced by TBK1/IKKɛ complex inhibitor BX795
por: Li, Lingyu, et al.
Publicado: (2020)

CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022)

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence
por: Wei, Wei, et al.
Publicado: (2023)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
por: Maalej, Karama Makni, et al.
Publicado: (2023)

Standardized in-vitro evaluation of CAR-T cells using acellular artificial target particles
por: Harari-Steinfeld, Rona, et al.
Publicado: (2022)

Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells
por: Zhao, Songbo, et al.
Publicado: (2021)

Stromal AR inhibits prostate tumor progression by restraining secretory luminal epithelial cells
por: Liu, Yueli, et al.
Publicado: (2022)

Dietary Regulation of Keap1/Nrf2/ARE Pathway: Focus on Plant-Derived Compounds and Trace Minerals
por: Stefanson, Amanda L., et al.
Publicado: (2014)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

The Chromatin Assembly Factor 1 Promotes Rad51-Dependent Template Switches at Replication Forks by Counteracting D-Loop Disassembly by the RecQ-Type Helicase Rqh1
por: Pietrobon, Violena, et al.
Publicado: (2014)

Recovery of Arrested Replication Forks by Homologous Recombination Is Error-Prone
por: Iraqui, Ismail, et al.
Publicado: (2012)

Overhauling CAR T Cells to Improve Efficacy, Safety and Cost
por: Chicaybam, Leonardo, et al.
Publicado: (2020)

Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
por: Pellegrino, Marsha, et al.
Publicado: (2020)

Strategies for Improving the Efficacy of CAR T Cells in Solid Cancers
por: Kyte, Jon Amund
Publicado: (2022)

Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion
por: Gumber, Diana, et al.
Publicado: (2022)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Development of CAR-T Cell Persistence in Adoptive Immunotherapy of Solid Tumors
por: Fan, Jiaqiao, et al.
Publicado: (2021)

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
por: Kong, Yingjie, et al.
Publicado: (2023)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Chimeric antigen receptors (CARs) incorporating mutations in the IgG4 Fc spacer region to eliminate Fc receptor recognition results in improved CAR T cell persistence and anti-tumor efficacy
por: Jonnalagadda, Mahesh, et al.
Publicado: (2013)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Optimization of metabolism to improve efficacy during CAR-T cell manufacturing
por: Zhang, Meng, et al.
Publicado: (2021)

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility
por: Celichowski, Piotr, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety
por: Li, Huali, et al.
Publicado: (2021)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r2m1dovt77ejchvqgftrdt6f5o